Pharmaceutical company
Appears in 9 stories
Paused three autoimmune CAR-T trials after participant deaths
Novartis paused its autoimmune CAR-T trials this month after three patients died from a severe immune reaction, and Bristol Myers paused its own over similar inflammatory events. The same week, Kyverna Therapeutics released 12 months of follow-up data on miv-cel, its rival therapy, reporting sustained improvement in stiff person syndrome patients with no high-grade immune toxicity.
Updated 2 days ago
Competitor; markets Fabhalta (iptacopan) for IgAN
Roche's experimental IgA nephropathy drug sefaxersen met its phase 3 primary endpoint on September 23, cutting proteinuria versus placebo at 37 weeks in the IMAgINATION study. The result, from a prespecified interim look, was strong enough that Roche is taking it to health authorities and planning a medical meeting presentation.
Updated 3 days ago
Rival with ianalumab under FDA review
Sjögren's disease has no approved treatment in the US. Amgen just moved a step closer to ending that.
Updated 4 days ago
Competitor and ITM's largest lutetium-177 customer
Telix Pharmaceuticals, an Australian maker of cancer imaging and treatment agents, agreed on September 21 to buy German isotope producer ITM Isotope Technologies Munich. The deal is worth up to $2.35 billion all-in, with $1.65 billion paid upfront, most of it in Telix shares.
Updated 5 days ago
Investing $1.1B into new Campus Point headquarters
A venue called The Alexandria at 4150 Campus Point Court in San Diego applied for a California liquor license. The application appeared on the state's ABC licensing list on September 18, 2026.
Updated Sep 18
Facing investor pressure after two phase 3 failures
Novartis' experimental muscle-disease drug del-desiran failed its phase 3 Harbor trial, missing the primary endpoint and sending shares down. The drug was the centerpiece of the company's $12 billion acquisition of Avidity Biosciences, which closed last year.
Updated Sep 8
Manufacturer of Kymriah, first FDA-approved CAR-T therapy
Gene therapy killed Jesse Gelsinger in 1999. His death triggered FDA shutdowns and nearly ended the field.
Updated Jul 3
Incumbent competitor in CML market with Scemblix
Keytruda, the world's best-selling drug, generated $31.7 billion for Merck in 2025 — roughly 40% of the company's total revenue. Its key U.S. patents expire in 2028, and when they do, cheaper copies will enter the market and that revenue will begin to evaporate. Merck has now spent over $25 billion on three acquisitions in nine months to build the portfolio that will need to replace it.
Updated May 30
Competitor; developing oral BTK inhibitor for food allergy
For decades, the 27 million American adults and children with food allergies had one option: avoid the allergen and carry an EpiPen. That changed in February 2024 when the FDA approved Xolair as the first drug to reduce allergic reactions—including anaphylaxis—from accidental exposure to multiple foods.
Updated May 22
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
